CytomX Therapeutics (CTMX) Stock Forecast, Price & News

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

Is CytomX Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CytomX Therapeutics stock.
View analyst ratings for CytomX Therapeutics or view top-rated stocks.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 3,800,000 shares, an increase of 37.7% from the April 15th total of 2,760,000 shares. Based on an average daily trading volume, of 971,800 shares, the days-to-cover ratio is currently 3.9 days. Approximately 6.2% of the company's stock are sold short.
View CytomX Therapeutics' Short Interest.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for CytomX Therapeutics.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. CytomX Therapeutics had a negative trailing twelve-month return on equity of 91.89% and a negative net margin of 129.97%. During the same period in the previous year, the firm earned ($0.26) earnings per share.
View CytomX Therapeutics' earnings history.

What price target have analysts set for CTMX?

6 Wall Street analysts have issued 12-month price targets for CytomX Therapeutics' stock. Their forecasts range from $6.00 to $16.00. On average, they anticipate CytomX Therapeutics' stock price to reach $10.83 in the next twelve months. This suggests a possible upside of 590.0% from the stock's current price.
View analysts' price targets for CytomX Therapeutics or view top-rated stocks among Wall Street analysts.

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:

• Dr. Sean A. McCarthy D.Phil., DPHIL, Chairman & CEO (Age 55, Pay $980.33k)
• Dr. Amy C. Peterson M.D., Pres & COO (Age 55, Pay $792.41k)
• Mr. Frederick W. Gluck, Co-Founder & Independent Director (Age 87, Pay $40k)
• Mr. Carlos Campoy, Sr. VP & CFO (Leave of Absence) (Age 56, Pay $678.35k)
• Mr. Lloyd A. Rowland Jr., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 65, Pay $594.07k)
• Dr. Alison L. Hannah M.D., Sr. VP & Chief Medical Officer (Age 61, Pay $659.8k)
• Mr. Christopher W. Ogden, Interim Principal Accounting Officer and VP of Fin. & Accounting (Age 38)
• Dr. Chau Cheng M.B.A., Ph.D., VP of Investor Relations & Corp. Communications
• Ms. Danielle Olander, Sr. VP, Talent & Systems Devel.
• Ms. Leslie Robbins, Sr. VP of Intellectual Property

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

Who are some of CytomX Therapeutics' key competitors?

Some companies that are related to CytomX Therapeutics include Pardes Biosciences (PRDS), Nuvalent (NUVL), Esperion Therapeutics (ESPR), Repare Therapeutics (RPTX), Tyra Biosciences (TYRA), Protagonist Therapeutics (PTGX), Inventiva (IVA), RAPT Therapeutics (RAPT), BioXcel Therapeutics (BTAI), Heron Therapeutics (HRTX), OrganiGram (OGI), Edgewise Therapeutics (EWTX), Gelesis (GLS), Arbutus Biopharma (ABUS) and Zymeworks (ZYME).
View all of CTMX's competitors.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include RTW Investments LP (8.84%), Vanguard Group Inc. (7.99%), BlackRock Inc. (7.63%), Candriam Luxembourg S.C.A. (2.53%), Healthcare of Ontario Pension Plan Trust Fund (1.97%) and State Street Corp (1.83%).
View institutional ownership trends for CytomX Therapeutics.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, RTW Investments LP, Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Northern Trust Corp, Engineers Gate Manager LP, California State Teachers Retirement System, and MetLife Investment Management LLC.
View insider buying and selling activity for CytomX Therapeutics or view top insider-selling stocks.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Acadian Asset Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Vanguard Group Inc., XTX Topco Ltd, and CI Investments Inc..
View insider buying and selling activity for CytomX Therapeutics or or view top insider-buying stocks.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $1.57.

How much money does CytomX Therapeutics make?

CytomX Therapeutics has a market capitalization of $102.67 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83.61 million in net income (profit) each year or ($1.420010) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

CytomX Therapeutics employs 174 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (605) 515-3185, via email at [email protected], or via fax at 650-351-0353.